Tonix Pharmaceuticals Reports Issuance Of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) For The Treatment Of Pain
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has been granted a European Union patent for its intranasal potentiated oxytocin (TNX-1900) for pain treatment. The patent is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036.
October 04, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The issuance of the EU patent for TNX-1900 is a positive development for Tonix Pharmaceuticals, potentially strengthening its market position in Europe until 2036.
The issuance of a patent provides Tonix Pharmaceuticals with market exclusivity for TNX-1900 in the member states of the European Patent Office until 2036. This exclusivity could potentially lead to increased revenues and profitability for the company, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100